Villeneuve-lès-Avignon, France

Grégory Durand

USPTO Granted Patents = 2 

Average Co-Inventor Count = 3.4

ph-index = 2

Forward Citations = 11(Granted Patents)


Company Filing History:


Years Active: 2010-2012

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Grégory Durand: Innovator in Medicinal Chemistry

Introduction

Grégory Durand is a notable inventor based in Villeneuve-lès-Avignon, France. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds aimed at treating oxidative stress-related diseases. With a total of 2 patents, his work reflects a commitment to advancing medical science.

Latest Patents

Durand's latest patents include innovative compounds derived from α-C-phenyl-N-tert-butylnitrone. The first patent details a process for the preparation of these compounds and their use in creating medicaments for preventing or treating oxidative stress-related diseases. The second patent focuses on novel compounds and derivatives of α-C-phenyl N-tert-butyl nitrone, outlining a method for their production and application in the prevention and treatment of diseases associated with oxidative stress.

Career Highlights

Throughout his career, Grégory Durand has worked with reputable organizations such as Ts Pharma and Université d'Avignon et des Pays du Vaucluse. His experience in these institutions has allowed him to collaborate with other professionals in the field, enhancing his research and development efforts.

Collaborations

Some of his notable coworkers include Ange Polidori and Bernard Pucci. Their collaborative efforts have contributed to the advancement of research in medicinal chemistry.

Conclusion

Grégory Durand's innovative work in the field of medicinal chemistry, particularly through his patents, showcases his dedication to improving health outcomes. His contributions are significant in the ongoing fight against oxidative stress-related diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…